For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Bristol-Myers Squibb CompanyBMY US · Health Care · USD Current price$58.34as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 4Buy 6Hold 17Sell 124 analysts 3-year price (USD)Factor profileMulti-factor score 93 / 100 Market data
Business descriptionBristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, cardiovascular, and immunology therapeutics. Its portfolio is concentrated on three top-selling drugs — Revlimid, Eliquis, and Opdivo — comprising 57% of 2025 revenue. The company is navigating a patent cliff transition. Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 11, 2026
Current price: $58.34 · Nov 20, 2026· USD
CFRA Ratinghold
TBI Multi Score93
Theme Exposure
Related Peers
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: BMYBusiness description
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, cardiovascular, and immunology therapeutics. Its portfolio is concentrated on three top-selling drugs — Revlimid, Eliquis, and Opdivo — comprising 57% of 2025 revenue. The company is navigating a patent cliff transition.
Competitive moat
- Oncology Franchise: Opdivo (~$2.5B/quarter, though down ~4% Y/Y as the U.S. market converts to the subcutaneous Opdivo Qvantig formulation, which is itself annualizing above $1B).
- Cardiovascular Leadership: Eliquis (~$4.5B in Q2 2026, +21% Y/Y) remains a top global anticoagulant with continued share gains; FY2026 Eliquis growth guided to 20-25%.
- Growth Portfolio Diversification: Newer drugs (Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy) delivered $7.6B in Q2 2026 (+15% Y/Y), now outweighing the legacy, patent-exposed portfolio ($5.4B, declining) — evidence the post-patent-cliff transition is gaining traction.
- First-in-Class Pipeline Optionality: Cobenfy (first non-dopaminergic antipsychotic), CELMoD candidates iberdomide (FDA Breakthrough Therapy/Priority Review, PDUFA 08/17/2026) and mezigdomide (positive interim Phase III SUCCESSOR-2 readout), positioned as next-generation Revlimid/Pomalyst successors in multiple myeloma.
- BioNTech Oncology Alliance: Global co-development/co-commercialization deal for bispecific pumitamig (BNT327) across multiple solid tumors, sharing costs and profits equally and broadening the next-generation oncology pipeline beyond BMS's own R&D.
Recent developments
- 2026-08-10: BMS announced a ~$2.3B investment in a new 600,000 sq. ft. multi-modal manufacturing campus in Houston, TX (Generation Park), creating ~500 skilled jobs plus ~2,000 construction jobs (2027-2030), part of the company's broader $40B, five-year U.S. manufacturing/R&D commitment.
- 2026-07-30 (Q2 2026 earnings): Revenue rose to ~$13.0B (+6% Y/Y); non-GAAP EPS $2.04 beat consensus of ~$1.59-1.60; company raised full-year 2026 revenue guidance to $49-50B and non-GAAP EPS guidance to $6.75-7.00.
- 2026-07-29: Shares set a new 52-week high (~$68.10) following the earnings beat, up ~15.5% over the trailing month and ~21% YTD.
- 2026-05 (ASCO 2026): BMS presented 60+ data disclosures across its oncology pipeline, including a positive interim PFS readout for mezigdomide in the Phase III SUCCESSOR-2 trial and combination data for iberdomide in newly diagnosed multiple myeloma — both positioned to succeed Revlimid/Pomalyst as generic erosion continues.
- 2026 (Cobenfy launch trajectory): Continued U.S. commercial ramp of Cobenfy in schizophrenia, with a UK launch planned in 2026 at U.S.-equivalent list pricing; analysts (e.g., Cantor Fitzgerald) project the drug approaching ~$1B in annual sales in 2026, scaling toward $3B+ by 2030.
- Ongoing (patent cliff): Full generic competition for Revlimid (lenalidomide) expanded through the volume-limited settlement structure, with Pomalyst generics also expected to enter the U.S. market in Q1 2026 — Legacy Portfolio revenue continues to decline (-5% Y/Y in Q2 2026) even as Eliquis and the Growth Portfolio more than offset the erosion at the total-company level.
Investment risks / red flags
- ⚠️ Patent Cliff / Legacy Erosion: Revlimid and Pomalyst face expanding generic competition through 2026, with Legacy Portfolio revenue already declining; the pace of erosion versus Growth Portfolio offset remains a key swing factor for out-year revenue.
- ⚠️ Opdivo Franchise Transition: Core IV Opdivo revenue is shrinking (-4% Y/Y in Q2 2026) as the market converts to Opdivo Qvantig; successful conversion economics (pricing, market access) are not yet fully proven at scale, and BMS trails Merck's Keytruda by a wide margin in immuno-oncology share.
- ⚠️ Pipeline Execution Risk: The bull case leans heavily on CELMoDs (iberdomide, mezigdomide), Cobenfy, and the BioNTech-partnered pumitamig reaching commercial scale; delayed approvals (e.g., iberdomide's 08/17/2026 PDUFA date), disappointing pivotal data, or slower-than-expected uptake would pressure the growth narrative.
- ⚠️ Capital Deployment / M&A Risk: Continued large licensing/M&A commitments (BioNTech's up-to-$11.1B deal, the $40B U.S. manufacturing pledge including the new $2.3B Houston campus) add integration and capital-allocation risk against a backdrop of already-elevated legacy revenue declines.
- ⚠️ Competitive Intensity: Oncology and immunology overlap heavily with Merck, J&J, Roche, AbbVie, and Pfizer, all of which are also investing aggressively in next-generation immuno-oncology and bispecific/ADC pipelines.
Market Data
Source: mkts.io · Nov 20, 2026, 02:01 UTC
Key Metrics
P/E (TTM)12.94
P/E (Fwd)8.71
Dividend4.23%
Beta0.19
52W High$68.64
52W Low$45.27
Analyst Consensus
4
6
17
Strong Buy4Buy6Hold17Sell124 analysts
Consensus Target$65.25
+11.8% upside
Calendar Events
Next EarningsOct 29, 2026
Ex-DividendOct 2, 2026
Dividend DateNov 2, 2026
Financials
Revenue$50.03B
Rev Growth6.90%
Earnings Growth-2.80%
Gross Margin70.50%
Op Margin32.37%
Profit Margin18.47%
EBITDA$18.24B
ROA10.90%
ROE44.01%
Rev/Share$24.54
Total Cash$12.58B
Total Debt$44.81B
D/E Ratio191.46
Free Cash Flow$6.36B
Op Cash Flow$10.65B
Current Ratio1.59
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 1.50 | $12.67B |
| +1q | 1.52 | $11.17B |
| 0y | 6.45 | $50.23B |
| +1y | 6.70 | $48.80B |
Earnings
Quarterly EPS
4Q2025
Est: 1.201.26Beat
1Q2026
Est: 1.421.58Beat
2Q2026
Est: 1.602.04Beat
3Q2026
Est: 1.171.35Beat
Annual
2022
Rev $46.16BEarn $6.33B
2023
Rev $45.01BEarn $8.03B
2024
Rev $48.30BEarn -$8.95B
2025
Rev $48.19BEarn $7.05B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Underweight |
| Oct 26, 2026 | Piper Sandler | main | Overweight |
| Oct 13, 2026 | Wells Fargo | main | Equal-Weight |
| Oct 8, 2026 | Cantor Fitzgerald | main | Neutral |
| Oct 7, 2026 | Morgan Stanley | main | Underweight |
| Oct 5, 2026 | Leerink Partners | down | Market Perform |
